EY bolsters UK&I life sciences practice with Guidehouse team

03 March 2021 Consultancy.uk 3 min. read
Profile
More news on

Building on strong demand for its services, EY had over the last few months added nearly 40 professionals to its Life Sciences practice in the UK and Ireland. The intake of new hires includes a senior team carved-out from rival Guidehouse.

In the UK, Ravi Degun has joined EY in London, appointed as a partner and global head of the Life Sciences Commercial Access practice. He previously served Guidehouse (formerly Navigant) for nearly a decade, latterly as a partner. Earlier in his career, Degun worked for PA Consulting and Accenture, and Thomson Reuters where he supported the setup of a consulting capability for the Life Science and Healthcare division.

He is a specialist in commercial launch, portfolio strategy and market access, and has supported dozens of biopharma and med-tech clients globally across different therapeutic areas.Ravi Degun, Mark Chalmers, Alex Charitou, Stuart MacGregor, Nina Marinsek,Nicholas Georgitseas and Binara RupasingheBased in Ireland, Mark Chalmers has been appointed a partner in EY’s Dublin office. He specialises in global commercial strategy, including international pricing and market access for pharmaceutical and biotech companies. Chalmers also joined from Navigant, where he was a director, and previously served strategic pharma consultancy CBPartners, Simon-Kucher & Partners and Capgemini Invent, among others.

He brings extensive experience in healthcare systems and health technology assessments with a deep knowledge of oncology, rare diseases, cell and gene-based therapies to the Big Four firm. 

Alex Charitou has been appointed an associate partner at EY. He has more than 20 years of experience in healthcare and life sciences with a focus on strategic commercial opportunity assessments, clinical advisory, and regulatory strategy supporting both medical technology and pharmaceutical companies. 

Stuart MacGregor has over 15 years of pharma industry experience in commercial strategy, including new product planning and early commercialisation, brand & lifecycle management strategy, and launch readiness. Prior to Guidehouse, MacGregor was the Vice President of Global Marketing for the Women’s Cancer & DDR Franchise, and spent a decade at Roche. MacGregor is an associate partner. 

Nina Marinsek previously worked around a decade for Guidehouse in London. She specialises in patient/caregiver research, clinical development & product/portfolio strategy in oncology and rare diseases. She joined the consultancy after obtaining her PhD from the University of Cambridge. Marinsek is an associate partner. 

Other members that have joined EY in the UK & Ireland from Guidehouse are Nicholas Georgitseas and Binara Rupasinghe – both have been appointed a director. 

Commenting on the team hire, Dan Mathews, EY EMEIA Life Sciences Market Lead, said: “It is with great pleasure that we welcome the team, bringing a wealth of global experience and in-depth market knowledge. This is a significant and timely investment in our life sciences consulting capability.”

According to Consultancy.org, EY’s is one of the leading global consulting firms to the pharma, life sciences and biotech industry.